Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

4.250 -0.150 (-3.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 Next >
Why Is Fatty Liver Disease Focused Sagimet Biosciences Stock Shooting Higher Today?
Sagimet Biosciences reports positive results from FASCINATE-2 Phase 2b trial. Denifanstat demonstrates significant improvements in NASH patients with fibrosis at week 52. 
Via Benzinga
US Stocks Higher; Nasdaq Jumps 100 Points
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded up 0.55% to 38,073.10 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Informa Tech's digital businesses. TechTarget shares surged... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
From Sagimet Biosciences Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
From Sagimet Biosciences Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Sagimet Biosciences Announces Leadership Changes
From Sagimet Biosciences Inc.
Via GlobeNewswire
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... 
Via Talk Markets
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.